Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
- PMID: 10595958
- DOI: 10.1161/01.cir.100.24.2443
Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
Abstract
Background: Neutral endopeptidase 24.11 (NEP) is a metalloprotease that is localized in the greatest abundance in the kidney and degrades natriuretic peptides, such as atrial natriuretic peptide (ANP). Mild congestive heart failure (CHF) is characterized by increases in circulating ANP without activation of the renin-angiotensin-aldosterone system (RAAS) or sodium retention. In contrast, severe CHF is characterized by sodium retention and coactivation of both ANP and the RAAS.
Methods and results: We defined the acute cardiorenal actions of the NEP inhibitor candoxatrilat (8 microg. kg(-1). min(-1)) in 4 groups of anesthetized dogs (normal, n=8; mild CHF, n=6; severe CHF, n=5; and severe CHF with chronic AT(1) receptor antagonism, n=5). Mild CHF was produced by rapid ventricular pacing at 180 bpm for 10 days and severe CHF at 245 bpm for 10 days. In mild CHF, urinary sodium excretion and glomerular filtration rate were greatest in response to acute NEP inhibition compared with the response in either control animals or those with severe CHF. Furthermore, an increase in glomerular filtration rate was observed only in mild CHF in association with increases in renal blood flow and decreases in renal vascular resistance and distal tubular sodium reabsorption. Urinary ANP and cGMP excretion, markers for renal biological actions of ANP, were greatest in mild CHF. The renal actions observed in mild CHF were attenuated in severe CHF and not restored by chronic AT(1) receptor antagonism.
Conclusions: The results of the present study demonstrate that acute NEP inhibition in mild CHF results in marked increases in renal hemodynamics and sodium excretion that exceed that observed in control animals and severe CHF. These studies underscore the potential therapeutic role for NEP inhibition to enhance renal function in mild CHF, an important phase of CHF that is marked by selective activation of endogenous ANP in the absence of an activated RAAS.
Similar articles
-
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.Kidney Int. 2005 May;67(5):1723-30. doi: 10.1111/j.1523-1755.2005.00269.x. Kidney Int. 2005. PMID: 15840018
-
Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.Hypertension. 2001 Aug;38(2):187-91. doi: 10.1161/01.hyp.38.2.187. Hypertension. 2001. PMID: 11509474
-
Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.J Clin Invest. 1991 Nov;88(5):1636-42. doi: 10.1172/JCI115477. J Clin Invest. 1991. PMID: 1658047 Free PMC article.
-
Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.Clin Exp Pharmacol Physiol. 1995 Jan;22(1):63-9. doi: 10.1111/j.1440-1681.1995.tb01920.x. Clin Exp Pharmacol Physiol. 1995. PMID: 7768036 Review.
-
Mechanisms of renal hyporesponsiveness to ANP in heart failure.Eur J Clin Invest. 2003 Sep;33(9):769-78. doi: 10.1046/j.1365-2362.2003.01222.x. Eur J Clin Invest. 2003. PMID: 12925036 Review.
Cited by
-
Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.Curr Cardiol Rep. 2016 Dec;18(12):127. doi: 10.1007/s11886-016-0807-9. Curr Cardiol Rep. 2016. PMID: 27796865 Review.
-
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.J Am Soc Nephrol. 2006 Oct;17(10):2742-7. doi: 10.1681/ASN.2006020161. Epub 2006 Aug 23. J Am Soc Nephrol. 2006. PMID: 16928803 Free PMC article.
-
Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.JACC Basic Transl Sci. 2022 Sep 7;8(1):88-105. doi: 10.1016/j.jacbts.2022.05.010. eCollection 2023 Jan. JACC Basic Transl Sci. 2022. PMID: 36777165 Free PMC article. Review.
-
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".Circulation. 2010 Jul 27;122(4):370-8. doi: 10.1161/CIRCULATIONAHA.109.915215. Epub 2010 Jul 12. Circulation. 2010. PMID: 20625113 Free PMC article.
-
BNP and Heart Failure: Preclinical and Clinical Trial Data.J Cardiovasc Transl Res. 2015 Apr;8(3):149-57. doi: 10.1007/s12265-015-9619-3. Epub 2015 Mar 14. J Cardiovasc Transl Res. 2015. PMID: 25771949 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous